Epitalon is a synthetic peptide modelled on an extract of the pineal gland. It is studied for its reported effect on telomerase, the enzyme that maintains the protective ends of chromosomes.
Epitalon · Synthetic pineal tetrapeptide
Each time a cell divides, the protective caps on its chromosomes, the telomeres, get a little shorter. Once they are short enough the cell stops dividing. Researchers ask whether that limit can be altered and what happens if it is. Epitalon is studied in that context. The evidence is cell culture and rodent work from one research programme; the human studies concern a related gland extract, not the peptide.
Epitalon (also written Epithalon) is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, Ala-Glu-Asp-Gly. It was designed at the St Petersburg Institute of Bioregulation and Gerontology as a synthetic counterpart to Epithalamin, a polypeptide extract of bovine pineal gland studied in the Soviet Union from the 1970s. The extract and the tetrapeptide are different substances, and findings for one do not automatically belong to the other.
The mechanism most often cited is induction of telomerase. Telomerase is the enzyme that rebuilds telomeres, and most adult cells keep it switched off. Khavinson et al. (2003) reported that adding Epitalon to cultured human fetal fibroblasts, which are normally telomerase-negative, induced expression of the enzyme's catalytic subunit, measurable telomerase activity and longer telomeres. The same programme also reports effects on evening melatonin production in aged animals, and proposes that very short peptides act by binding DNA directly; that proposal rests on molecular modelling and remains a hypothesis.
Cell culture. In a follow-up, Khavinson et al. (2004) reported that fetal lung fibroblasts treated with Epitalon made about ten extra divisions beyond the passage at which untreated cells stopped, the so-called Hayflick limit.
Animals. Anisimov et al. (2003) injected female SHR mice with Epitalon on five days each month from three months of age until death, 54 mice per group. Mean lifespan did not differ from control. The last ten per cent of survivors lived 13.3 per cent longer, maximum lifespan was 12.3 per cent longer, the decline of oestrous cycling was slower and bone-marrow chromosome aberrations were fewer; total spontaneous tumour incidence was unchanged. In aged rhesus monkeys, Epitalon increased evening melatonin and altered the daily rhythm of cortisol.
People. The only long-term human study in this literature used Epithalamin, the gland extract, not Epitalon. Korkushko et al. (2006) followed elderly patients with coronary disease for twelve years and reported lower mortality in the extract-treated group. That result cannot be transferred to the synthetic tetrapeptide, and the report gives few design details. A 2010 review by Anisimov and Khavinson consolidates the programme's rodent and clinical work.
No lifespan finding exists for Epitalon in people, and the mouse study found no change in mean lifespan. Almost all primary work comes from one group of affiliated laboratories, and independent replication is limited. Telomerase activation is not straightforwardly desirable: the enzyme is active in most cancers, so a compound that switches it on in normal cells raises a safety question that cell culture cannot answer. The DNA-binding mechanism is a model, not a demonstrated event in living tissue. The extract and the peptide must be read as separate evidence bases.
Epitalon is not an approved medicine in Australia. No regulator-approved Epitalon medicine was identified in any jurisdiction for this note; the related Epithalamin extract has a separate history within the former Soviet Union and Russia that this note does not assess.
Sources and status checked 2026-09-22
Epitalon — sizes and pricing